Published in

BMJ Publishing Group, International Journal of Gynecological Cancer, 5(14), p. 875-881, 2004

DOI: 10.1136/ijgc-00009577-200409000-00021

BMJ Publishing Group, International Journal of Gynecological Cancer, 5(14), p. 875-881

DOI: 10.1111/j.1048-891x.2004.14524.x

Links

Tools

Export citation

Search in Google Scholar

Vulvar cancer patients' quality of life: A qualitative assessment

Journal article published in 2004 by M. Janda ORCID, A. Obermair ORCID, D. Cella, Aj J. Crandon, M. Trimmel
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

To develop a vulvar cancer-specific quality of life (QOL) subscale to accompany the Functional Assessment of Cancer–General (FACT-G) questionnaire, semistructured interviews were performed with 15 patients treated for vulvar cancer (FIGO stage 0–3). All but one patient, who received chemoradiotherapy, were treated by radical vulvectomy and six patients received a groin lymph node dissection. Patients experienced reductions in several aspects of QOL including emotional functioning, physical functioning, social functioning, sexuality, and body image. Six patients suffered from lymphedema of the legs with a mean severity of 3.5 on a 10-point scale. Four patients reported pruritus (severity rating 8.5). Seven patients expressed a need for more information about the illness and treatment. Only four patients returned to employment after treatment, and all of these patients reported work-related problems. Reductions in sexual functioning were a major concern for five patients, all younger than 65 years. Other topics were groin discomfort after removal of the lymph nodes and disturbance by odor from the vulva. Results of this study revealed vulvar cancer-specific reductions in QOL for inclusion in the newly developed vulvar cancer-specific subscale. © 2004 IGCS